Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.53 |
| ▸ | RAB9A | P51151 | 6/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | TP53 | P04637 | 4/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | MITF | O75030 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | XBP1 | P17861 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22754972 | 0.84 | MAPT (0.47) | MAPTRAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL22754983 | 0.82 | MAPT (0.53) | MAPTRAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL29839337 | 0.81 | MAPT (0.50) | MAPTRAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL22729511 | 0.81 | MAPT (0.50) | MAPTRAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL22729814 | 0.70 | PKM (0.55) | MAPTRAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL22729727 | 0.70 | ALDH1A1 (0.32) | MAPTALDH1A1PKMLMNAKDM4E | |
| SCHEMBL22729654 | 0.70 | TDP1 (0.52) | MAPTRAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL22729512 | 0.69 | KDM4E (0.39) | MAPTRAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL22755193 | 0.69 | NPC1 (0.47) | RAB9ASMN1; SMN2ALDH1A1NPC1LMNA | |
| SCHEMBL22729636 | 0.69 | MAPT (0.55) | MAPTRAB9ASMN1; SMN2ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459325-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-04 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| EP-3747885-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | MAPT 356/4885RAB9A 239/4885SMN1; SMN2 151/4885 |
| US-11459325-B2 | Heterocyclic compound | GBA1, GBA2, GALC | MAPT 364/4885RAB9A 239/4885SMN1; SMN2 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.